Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsOVID -7.12%34 3-Year Book Growth Rate is -18.80% as of Jun. 2026. GuruFocus rates OVID with a GF Score™ of 34/100 and a GF Value™ of $0.97 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,132 Biotechnology companies, Ovid Therapeutics ranks worse than 62.1% on this metric.
During the past 12 months, Ovid Therapeutics's average Book Value per Share Growth Rate was 44.70% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -18.80% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -3.60% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -8.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Ovid Therapeutics was 23.20% per year. The lowest was -41.90% per year. And the median was -15.50% per year.
Ovid Therapeutics (NAS:OVID) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Ovid Therapeutics 3-Year Book Growth Rate Related Terms
OVID vs SGMT, CABA, QTTB: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Ovid Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's 3-Year Book Growth Rate falls into.
Ovid Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -18.80% mean?
Ovid Therapeutics (OVID) has a 3-Year Book Growth Rate of -18.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #703 out of 1132 companies in the Biotechnology industry, placing it in the top 62.1%.
Is Ovid Therapeutics' 3-Year Book Growth Rate too high?
Ovid Therapeutics' current 3-Year Book Growth Rate is -18.80%. Based on the distribution chart, Ovid Therapeutics ranks #703 out of 1132 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' 3-Year Book Growth Rate compare to SGMT and CABA?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #703 out of 1132 companies for 3-Year Book Growth Rate. This places Ovid Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Ovid Therapeutics and its competitors. Ovid Therapeutics's current 3-Year Book Growth Rate is -18.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.97, compared to a current price of $2.74 — trading 182.5% above its estimated fair value. The current 3-Year Book Growth Rate is -18.80%. Ovid Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current 3-Year Book Growth Rate is -18.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued.
The current stock price of $2.74 is trading 182.5% above its estimated GF Value™ of $0.97.
GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.
Key valuation signals for OVID:
3-Year Book Growth Rate: -18.80%
GF Value™: $0.97 vs. price of $2.74 (182.5% above fair value)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score
Get the complete analysis for OVID
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
